What side effects are associated with this type of intervention?

Common treatments for Inflammatory Bowel Disease (IBD) such as anti-TNF agents (e.g., infliximab), IL-12/23 inhibitors (e.g., ustekinumab), and IL-17 inhibitors (e.g., secukinumab) share several side effects. These can include increased risk of infections, injection site reactions, and potential development of antibodies against the drug, which may reduce efficacy. Specific to IL-23 inhibitors like Mirikizumab, side effects may also include nasopharyngitis, headache, and upper respiratory infections. It is important to monitor for these adverse effects and discuss them with a healthcare provider to manage and mitigate risks effectively.

What prior FDA approvals exist?

The FDA has approved several biologic therapies for the treatment of Inflammatory Bowel Disease (IBD), including Ulcerative Colitis (UC) and Crohn's Disease (CD). These treatments primarily target inflammatory pathways. Notably, anti-TNF agents such as infliximab, adalimumab, and certolizumab pegol have been approved for both induction and maintenance of remission in CD. Additionally, ustekinumab, which targets IL-12 and IL-23, has been approved for patients who have failed other biologic therapies. Mirikizumab, currently under study, specifically targets IL-23, similar to ustekinumab, and aims to provide long-term efficacy in pediatric patients with UC or CD.

What other types of research exist?

Promising novel alternatives to Mirikizumab for IBD patients include: 1) Adalimumab (Humira) - a TNF-alpha inhibitor with proven efficacy in Crohn's disease and ulcerative colitis. 2) Infliximab (Remicade) - another TNF-alpha inhibitor effective in inducing and maintaining remission in IBD. 3) Certolizumab pegol (Cimzia) - a TNF inhibitor used as a second- or third-line treatment. 4) Tofacitinib (Xeljanz) - an oral Janus kinase inhibitor effective in ulcerative colitis. 5) Ustekinumab (Stelara) - an IL-12/23 inhibitor used for both Crohn's disease and ulcerative colitis. These alternatives offer different mechanisms of action and administration routes, providing various options for personalized treatment plans.

← Back to Search

Monoclonal Antibodies

Mirikizumab for Ulcerative Colitis (SHINE-ON Trial)

Phase 3

Recruiting

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Must not have

Participants must not have had permanently or temporarily stopped study drug in the originating study, such that restarting mirikizumab would pose an unacceptable risk for the participant in Study AMAZ.

Participants must not have adenomatous polyps that have not been removed.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 52

Awards & highlights

Summary

This trial is testing a medication called mirikizumab to see if it can help children with ulcerative colitis or Crohn's disease by reducing inflammation in their digestive tracts.

Who is the study for?

This trial is for pediatric patients who have ulcerative colitis or Crohn's disease and were part of previous mirikizumab studies. They should have completed the last study without serious side effects and could benefit from continued treatment. Girls must agree to use birth control, and participants can't join if they've had severe reactions before, stopped the drug due to risks, have unstable illnesses, untreated polyps, or are pregnant/breastfeeding.

What is being tested?

The trial tests the long-term effectiveness of a medication called mirikizumab in young patients with two types of inflammatory bowel diseases: ulcerative colitis and Crohn's disease. It spans roughly 172 weeks with up to 44 clinic visits to monitor how well the drug works over time.

What are the potential side effects?

While not explicitly listed here, common side effects for drugs like mirikizumab may include injection site reactions, increased risk of infection, headaches, fatigue, abdominal pain, and potential allergic responses.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have never stopped taking the study drug in a way that restarting it would be unsafe.

Select...

I do not have any unremoved adenomatous polyps.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 52

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 52

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 52 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Percentage of Participants with CD in Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission

Percentage of Participants with UC in Modified Mayo Score (MMS) Clinical Remission

Secondary study objectives

Percentage of Participants with CD Achieving Histologic Response

Percentage of Participants with CD in Corticosteroid-free Remission Without Surgery

Percentage of Participants with CD in Endoscopic Remission

+10 more

Trial Design

7Treatment groups

Experimental Treatment

Group I: Mirikizumab Dose 7 for UC or CDExperimental Treatment1 Intervention

Intravenous (IV) rescue dosing, if response is lost.

Group II: Mirikizumab Dose 6 for CDExperimental Treatment1 Intervention

Dose 6 of Mirikizumab is administered SC Dosing is based on the participant's weight.

Group III: Mirikizumab Dose 5 for CDExperimental Treatment1 Intervention

Dose 5 of Mirikizumab is administered SC Dosing is based on the participant's weight.

Group IV: Mirikizumab Dose 4 for CDExperimental Treatment1 Intervention

Dose 4 of Mirikizumab is administered SC Dosing is based on the participant's weight.

Group V: Mirikizumab Dose 3 for UCExperimental Treatment1 Intervention

Dose 3 of Mirikizumab is administered SC Dosing is based on the participant's weight.

Group VI: Mirikizumab Dose 2 for UCExperimental Treatment1 Intervention

Dose 2 of Mirikizumab is administered SC Dosing is based on the participant's weight.

Group VII: Mirikizumab Dose 1 for UCExperimental Treatment1 Intervention

Dose 1 of Mirikizumab is administered subcutaneously (SC) Dosing is based on the participant's weight.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Mirikizumab

2020

Completed Phase 3

~6070

0 / 2Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for Inflammatory Bowel Disease (IBD) include biological agents and traditional therapies. Mirikizumab, an IL-23 inhibitor, works by targeting and inhibiting the interleukin-23 pathway, which plays a crucial role in the inflammatory process of IBD. TNF inhibitors, such as infliximab and adalimumab, block tumor necrosis factor-alpha, a cytokine involved in systemic inflammation. Integrin inhibitors, like vedolizumab, prevent white blood cells from migrating to the gut, thereby reducing inflammation. Traditional therapies include corticosteroids, which suppress the immune system to reduce inflammation, and immunomodulators like azathioprine, which alter the immune response. These treatments are vital for IBD patients as they help manage symptoms, induce and maintain remission, and improve quality of life by targeting specific pathways involved in the disease's inflammatory process.

Positioning Therapies in the Management of Crohn's Disease.Early or late guided missile in the treatment of Crohn's disease?